2026-04-05T10:39:37Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/2249022025-12-17T13:01:19Zcom_2072_1057col_2072_478916col_2072_478917
RECERCAT author Capdevila, Jaume author Hernando, Jorge author Molina Cerrillo, Javier author Benavent Viñuales, Marta author Garcia Carbonero, Rocio author Teulé, Alex author Custodio, Ana author Jiménez Fonseca, Paula author López, Carlos author Hierro, Cinta author Carmona Bayonas, Alberto author Alonso, Vicente author Llanos, Marta author Sevilla, Isabel author García Alvárez, Alejandro author Alonso Gordoa, Teresa author Gallego Jiménez, Inmaculada author Anton Pascual, Beatriz author Modrego Sánchez, Andrea author Grande, Enrique 2025-12-15T09:40:57Z2025-12-15T09:40:57Z2025-09-122025-12-02T09:19:17Z Purpose: Multikinase inhibitors have shown efficacy in endocrine neoplasms, and synergism with immune checkpoint inhibitors has been noted in other tumors.Patients and Methods: This is a prospective, multicenter, open-label, Simon two-stage optimal design, phase II study including patients with advanced and refractory endocrine and neuroendocrine neoplasms in six cohorts: lung well-differentiated neuroendocrine tumors, anaplastic thyroid cancer (ATC), adrenocortical carcinoma (ACC), pheochromocytoma/paraganglioma (PPGL), well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET), and grade 3 extrapulmonary neuroendocrine neoplasms. Patients received atezolizumab 1,200 mg intravenously every 3 weeks plus cabozantinib 40 mg/day orally until disease progression or unacceptable toxicity. The primary objective was the overall response rate (ORR) by RECIST 1.1.Results: From October 2020 to December 2022, 93 patients were included. The ORR was 14.3% [95% confidence interval (CI), 1.8-42.8] in ATC (N = 14); 8.3% (95% CI, 1.0-27.0) in ACC (N = 24); 15.4% (95% CI, 1.9-45.5) in PPGL (N = 13), and 16.7% (95% CI, 4.7-37.4) in GEP-NET (N = 24). Lung well-differentiated neuroendocrine tumors and grade 3 extrapulmonary neuroendocrine neoplasms had no responses. The duration of response was 20.4 months in ATC, 13.1 months in ACC, 12.2 months in PPGL, and 15.8 months in GEP-NET. Survival rates at 12 months in ATC and ACC were 47.6% and 47.6%, respectively. No unexpected toxicity was observed.Conclusions: Cabozantinib and atezolizumab were safely administered and showed promising ORR, and preliminary long-term survival rates were observed in aggressive and pretreated ACC and ATC, which warrants further investigation. cc-by-nc-nd (c) Capdevila, Jaume et al., 2025 https://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Assaigs clínics Dianes farmacològiques Càncer de tiroide Clinical trials Drug targeting Thyroid gland cancer Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914) info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion